<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Epidemiоlоgy and infectious diseases. Сurrent items</journal-id><journal-title-group><journal-title xml:lang="en">Epidemiоlоgy and infectious diseases. Сurrent items</journal-title><trans-title-group xml:lang="ru"><trans-title>Эпидемиология и инфекционные болезни. Актуальные вопросы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2226-6976</issn><issn publication-format="electronic">2414-9640</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">716301</article-id><article-id pub-id-type="doi">10.18565/epidem.2026.16.2.84-92</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Investigations</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical and epidemiological characteristics of imported cases of dengue fever depending on the molecular genetic properties of the pathogen and the levels of endothelial dysfunction markers</article-title><trans-title-group xml:lang="ru"><trans-title>Клинико-эпидемиологическая характеристика завозных случаев лихорадки денге в зависимости от молекулярно-генетических свойств возбудителя и уровня маркеров эндотелиальной дисфункции</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-6748-6786</contrib-id><name-alternatives><name xml:lang="en"><surname>Luzhetskayа</surname><given-names>Alexandra A.</given-names></name><name xml:lang="ru"><surname>Лужецкая</surname><given-names>Александра Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate Student; Physician, 7th Infectious Diseases Department</p></bio><bio xml:lang="ru"><p>аспирант; врач 7-го инфекционного отделения</p></bio><email>luzhetskaya.98@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2570-711X</contrib-id><name-alternatives><name xml:lang="en"><surname>Pshenichnaya</surname><given-names>Natalia Yu.</given-names></name><name xml:lang="ru"><surname>Пшеничная</surname><given-names>Наталья Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Professor, Deputy Director for Clinical and Analytical Work; Head, Department of Infectious Diseases; Professor, Department of Infectious Diseases</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, заместитель директора по клинико-аналитической работе; заведующая кафедрой инфекционных болезней; профессор кафедры инфекционных болезней</p></bio><email>pshenichnaya@cmd.su</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8703-7671</contrib-id><name-alternatives><name xml:lang="en"><surname>Gopatsa</surname><given-names>Galina V.</given-names></name><name xml:lang="ru"><surname>Гопаца</surname><given-names>Галина Витальевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Med, Sci., Senior Researcher, Clinical Department of Infectious Pathology; Head, 7th Infectious Diseases Department; Assistant Professor, Department of Infectious Diseases</p></bio><bio xml:lang="ru"><p>к.м.н., старший научный сотрудник клинического отдела инфекционной патологии; заведующая инфекционным отделением № 7; доцент кафедры инфекционных болезней</p></bio><email>galentinabk@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8407-2623</contrib-id><name-alternatives><name xml:lang="en"><surname>Morozkin</surname><given-names>Evgeny S.</given-names></name><name xml:lang="ru"><surname>Морозкин</surname><given-names>Евгений Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Chem. Sci., Head, Research Group for Developing New Methods for Diagnosing Natural Focal Diseases</p></bio><bio xml:lang="ru"><p>к.х.н., руководитель научной группы разработки новых методов диагностики природно-очаговых заболеваний</p></bio><email>morozkin@cmd.su</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4228-9044</contrib-id><name-alternatives><name xml:lang="en"><surname>Аkimkin</surname><given-names>Vasiliy G.</given-names></name><name xml:lang="ru"><surname>Акимкин</surname><given-names>Василий Геннадьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Academician of the Russian Academy, МD, Professor, Director</p></bio><bio xml:lang="ru"><p>академик РАН, д.м.н., профессор, директор</p></bio><email>crie@pcr.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being</institution></aff><aff><institution xml:lang="ru">Центральный НИИ эпидемиологии Роспотребнадзора</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Infectious Diseases Clinical Hospital № 1, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">Инфекционная клиническая больница № 1 Департамента здравоохранения города Москвы</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia</institution></aff><aff><institution xml:lang="ru">Российская медицинская академия непрерывного профессионального образования Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">M.F. Vladimirsky Moscow Regional Research Clinical Institute</institution></aff><aff><institution xml:lang="ru">Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-07-10" publication-format="electronic"><day>10</day><month>07</month><year>2026</year></pub-date><volume>16</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>84</fpage><lpage>92</lpage><history><date date-type="received" iso-8601-date="2026-07-10"><day>10</day><month>07</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-07-10"><day>10</day><month>07</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ООО «Бионика Медиа»</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://journals.eco-vector.com/2226-6976/about/editorialPolicies#purchaseIssue</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.eco-vector.com/2226-6976/article/view/716301">https://journals.eco-vector.com/2226-6976/article/view/716301</self-uri><abstract xml:lang="en"><p><bold>Objective. </bold>Comprehensive analysis of the clinical and epidemiological characteristics of imported cases of dengue fever (DF) in patients residing in non-endemic areas and evaluation of the relationship between disease severity, virus (DENV) serotype, and markers of endothelial dysfunction.</p> <p><bold>Materials and methods. </bold>The study included 51 patients with DF hospitalized in infectious disease hospitals in Moscow in 2024–2025. Serotyping was performed by PCR; IgM, IgG, and cytokines (tumor necrosis factor α, interleukins (IL) 1β, 8, 10) were determined by ELISA; von Willebrand factor was determined by agglutination. DF severity was assessed according to the WHO classification (2009).</p> <p><bold>Results. </bold>The study group was dominated by women (62.7%), the average age was 33.9 years. The main countries of importation were the Maldives, Thailand and Indonesia. The dominant serotype was DENV-3 (43.1%), less common were DENV-2 (31.4%) and DENV-1 (25.5%); DENV-4 was not detected. DENV-2 was more often associated with the importation of DF from the Maldives, DENV-3 - with Thailand and Sri Lanka. In the structure of forms, DF without precursors (DF-P) was predominant (64.7%), DF with precursors (LD+P) accounted for 33.3%, severe DF - 2.0%. All patients with DF+P and severe DF had hemorrhagic syndrome. The main symptoms were fever, weakness, arthralgia, rash and diarrhea. Leukopenia, lymphopenia and thrombocytopenia are characteristic. DENV-2 infection was associated with more pronounced leukotropenia and neutropenia, while DENV-3 infection was associated with elevated alanine aminotransferase levels. DF+P was more common in women and was associated with more pronounced hematological and coagulation abnormalities, as well as elevated IL-10 (<italic>p</italic> = 0.01) and von Willebrand factor (<italic>p</italic> = 0.024) levels.</p> <p><bold>Conclusion</bold>. The data obtained confirm the feasibility of using immunological, endothelial, and biochemical markers in combination with virus serotyping to improve epidemiological surveillance and assess the severity of imported cases of DF.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования.</bold> Комплексный анализ клинико-эпидемиологических особенностей завозных случаев лихорадки денге (ЛД) у пациентов, проживающих на неэндемичной территории, и оценка взаимосвязи между тяжестью заболевания, серотипом вируса (DENV) и маркерами эндотелиальной дисфункции.</p> <p><bold>Материалы и методы. </bold>В исследование включен 51 пациент с ЛД, госпитализированный в инфекционные стационары г. Москвы в 2024–2025 гг. Серотипирование выполняли методом ПЦР; IgM, IgG и цитокины (фактор некроза опухоли α, интерлейкины (ИЛ) 1β, 8, 10) определяли методом ИФА; фактор фон Виллебранда – методом агглютинации. Тяжесть ЛД оценивали по классификации ВОЗ (2009).</p> <p><bold>Результаты. </bold>В исследуемой группе преобладали женщины (62,7%), средний возраст составил 33,9 года. Основные страны завоза: Мальдивы, Таиланд и Индонезия. Доминировал серотип DENV-3 (43,1%), реже встречались DENV-2 (31,4%) и DENV-1 (25,5%); DENV-4 не выявлен. DENV-2 чаще ассоциировался с завозом ЛД с Мальдив, DENV-3 – с Таиландом и Шри-Ланкой. В структуре форм преобладала ЛД без предвестников (ЛД-П) (64,7%), ЛД с предвестниками (ЛД+П) составила 33,3%, тяжелая ЛД – 2,0%. У всех пациентов с ЛД+П и тяжелой ЛД наблюдался геморрагической синдром. Основные симптомы: лихорадка, слабость, артралгии, сыпь и диарея. Характерны лейкопения, лимфопения и тромбоцитопения. При инфицировании DENV-2 отмечались более выраженные лейко- и нейтропения, DENV-3 – повышение уровня аланинаминотрансферазы. ЛД+П чаще встречалась у женщин, сопровождалась более выраженными гематологическими и коагуляционными нарушениями, а также повышением содержания ИЛ-10 (<italic>p</italic> = 0,01) и фактора фон Виллебранда (<italic>p </italic>= 0,024);</p> <p><bold>Заключение. </bold>Полученные данные подтверждают целесообразность использования иммунологических, эндотелиальных и биохимических маркеров в сочетании с серотипированием вируса для совершенствования эпидемиологического надзора и оценки тяжести течения завозных случаев ЛД.</p></trans-abstract><kwd-group xml:lang="en"><kwd>dengue fever</kwd><kwd>molecular genetic properties of dengue fever virus</kwd><kwd>markers of endothelial dysfunction</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лихорадка денге</kwd><kwd>молекулярно-генетические свойства вируса лихорадки денге</kwd><kwd>маркеры эндотелиальной дисфункции</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Osman S., Preet R. Dengue, chikungunya and Zika in GeoSentinel surveillance of international travellers: a literature review from 1995 to 2020. J. Travel Med. 2020; 27(8): taaa222. DOI: 10.1093/jtm/taaa222</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Dengue: guidelines for diagnosis, treatment, prevention and control. Geneva: World Health Organization, 2009, 149 р.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Namirimu T., Kim S. Dengue fever: epidemiology, clinical manifestations, diagnosis, and therapeutic strategies. Ann. Clin. Microbiol. 2024; 27(2): 131–141. DOI: 10.5145/ACM.2024.27.2.7</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Tricou V., Minh N.N., Farrar J., Tran H.T., Simmons C.P. Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. PLoS Negl. Trop. Dis. 2011; 5(9): e1309. DOI: 10.1371/journal.pntd.0001309</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Николаева Л.И., Ларичев В.Ф., Сайфуллин М.А., Дедова А.В., Гришечкин А.Е., Васильев А.В. и др. Анализ возможного влияния генетических факторов пациентов на течение инфекции, вызванной вирусом лихорадки денге. Инфекционные болезни: Новости. Мнения. Обучение 2022; 11(1): 8–14. [Nikolaeva L.I., Larichev V.F., Sayfullin M.A., Dedova A.V., Grishechkin A.E., Vasiliev A.V. et al. Analysis of the possible influence of patients’ genetic factors on the course of Dengue virus infectio. Infectious Diseases: News, Opinions, Training 2022; 11(1): 8–14. (In Russ.)]. DOI: 10.33029/2305-3496-2022-11-1-8-14</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Sahu R., Verma R., Jain A., Garg R.K., Singh M.K., Malhotra H.S. et al. Neurologic complications in dengue virus infection: a prospective cohort study. Neurology 2014; 83(18): 1601–1609. DOI: 10.1212/WNL.0000000000000935</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Malavige G.N., Ogg G.S. Pathogenesis of vascular leak in dengue virus infection. Immunology. 2017; 151(3): 261–269. DOI: 10.1111/imm.12748</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Gómez-Barrera S., Moreno-Hortua J.M., Gallego-Gómez J.C., de Schroeder M.M., Castaño-Osorio J.C. Dengue and endothelium: a perspective on the pathophysiological implications of endothelial activation in dengue and its therapeutic possibilities. Infectio 2025; 29(4): 228–238. DOI: 10.22354/24223794.1251</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Adikari T.N., Gomes L., Wickramasinghe N., Salimi M., Wijesiriwardana N., Kamaladasa A. et al. Dengue NS1 antigen contributes to disease severity by inducing interleukin (IL)-10 by monocytes. Clin. Exp. Immunol. 2016; 184(1): 90–100. DOI: 10.1111/cei.12747</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Djamiatun K., van der Ven A.J., de Groot P.G., Faradz S.M., Hapsari D., Dolmans W.M. Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13. PLoS Negl. Trop. Dis. 2012; 6(5): e1628. DOI: 10.1371/journal.pntd.0001628</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Raghupathy R., Chaturvedi U.C., Al-Sayer H., Elbishbishi E.A., Agarwal R., Nagar R. et al. Elevated levels of IL-8 in dengue hemorrhagic fever. J. Med. Virol. 1998; 56(3): 280–285. DOI: 10.1002/(sici)1096-9071(199811)56:3&lt; 280:aid-jmv18&gt;3.0.co;2-i</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Khanam A., Gutiérrez-Barbosa H., Lyke K.E., Chua J.V. Immune-Mediated Pathogenesis in Dengue Virus Infection. Viruses 2022; 14(11): 2575. DOI: 10.3390/v14112575</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Alexander N., Balmaseda A., Coelho I.C., Dimaano E., Hien T.T., Hung N.T. et al. European Union, World Health Organization (WHO‐TDR) supported DENCO Study Group. Multicentre prospective study on dengue classification in four South-east Asian and three Latin American countries. Trop. Med. Int. Health 2011; 16(8): 936–948. DOI: 10.1111/j.1365-3156.2011.02793.x</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Yuan K., Chen Y., Zhong M., Lin Y., Liu L. Risk and predictive factors for severe dengue infection: A systematic review and meta-analysis. PLoS One 2022; 17(4): e0267186. DOI: 10.1371/journal.pone.0267186</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Tsheten T., Clements A.C.A., Gray D.J., Adhikary R.K., Furuya-Kanamori L., Wangdi K. Clinical predictors of severe dengue: a systematic review and meta-analysis. Infect. Dis. Poverty 2021; 10(1): 123–132. DOI: 10.1186/s40249-021-00908-2</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Wilder-Smith A., Ooi E.E., Horstick O., Wills B. Dengue. Lancet 2019; 393(10169): 350–363. DOI: 10.1016/S0140-6736(18)32560-1</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Campana V., Inizan C., Pommier J.D., Menudier L.Y., Vincent M., Lecuit M. Liver involvement in dengue: A systematic review. Rev. Med. Virol. 2024; 34(4): e2564. DOI: 10.1002/rmv.2564</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Rodrigo C., Sigera C., Fernando D., Rajapakse S. Plasma leakage in dengue: a systematic review of prospective observational studies. BMC Infect. Dis. 2021; 21(1): 1082–1092. DOI: 10.1186/s12879-021-06793-2</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Masyeni S., Wardhana I.M.W., Nainu F. Cytokine profiles in dengue fever and dengue hemorrhagic fever: A study from Indonesia. Narra J. 2024; 4(1): e309. DOI: 10.52225/narra.v4i1.309</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Gomatheswari S.N., Poornakala R., Jeyamurugan J.T., Devi C.S. Assessment of Serum Interleukin-10 as a Marker of Severity in Dengue Virus Infection: A Cross-sectional Study. J. Clin. Diagn. Res. 2026; 20(3): DC24–DC27. DOI: 10.7860/JCDR/2026/78001.22563</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Balmaseda A., Hammond S.N., Pérez L., Tellez Y., Saborío S.I., Mercado J.C. et al. Serotype-specific differences in clinical manifestations of dengue. Am. J. Trop. Med. Hyg. 2006; 74(3): 449–456.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Soo K.M., Khalid B., Ching S.M., Chee H.Y. Meta-Analysis of Dengue Severity during Infection by Different Dengue Virus Serotypes in Primary and Secondary Infections. PLoS One 2016; 11(5): e0154760. DOI: 10.1371/journal.pone.0154760</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Halstead S.B. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiol. Spectr. 2014; 2(6). DOI: 10.1128/microbiolspec.AID-0022-2014</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Katzelnick L.C., Gresh L., Halloran M.E., Mercado J.C., Kuan G., Gordon A. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 2017; 358(6365): 929–932. DOI: 10.1126/science.aan6836</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Bhatt P., Jayaram A., Varma M., Mukhopadhyay C. Kinetics of dengue viremia and its association with disease severity: an ambispective study. Virusdisease 2024; 35(2): 250–259. DOI: 10.1007/s13337-024-00872-z</mixed-citation></ref></ref-list></back></article>
